MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

76.33 -1.14

Resumen

Variación precio

24h

Actual

Mínimo

74.52

Máximo

77.84

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-245M

-94M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+22.94% upside

Dividendos

By Dow Jones

Próximas Ganancias

18 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.6B

13B

Apertura anterior

77.47

Cierre anterior

76.33

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

159 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 ene 2026, 23:29 UTC

Acciones populares

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 ene 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ene 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 21:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ene 2026, 21:41 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ene 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ene 2026, 20:44 UTC

Ganancias

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ene 2026, 20:42 UTC

Charlas de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ene 2026, 20:28 UTC

Charlas de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ene 2026, 19:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 ene 2026, 18:53 UTC

Charlas de Mercado

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 ene 2026, 18:41 UTC

Charlas de Mercado

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 ene 2026, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 17:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 ene 2026, 17:03 UTC

Charlas de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 ene 2026, 16:32 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 ene 2026, 16:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

22.94% repunte

Estimación a 12 meses

Media 94.92 USD  22.94%

Máximo 110 USD

Mínimo 77 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

13

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

159 / 361 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat